Roche has entered into a collaboration with Warp Drive Bio aiming to discover and develop multiple classes of antibiotics with novel structures and mechanisms of action.
Under the alliance, Warp Drive will use its proprietary Genome Mining Platform to advance multiple novel classes of antibiotics with activity against clinically important, drug-resistant, Gram-negative pathogens.
The company said it is identifying and evaluating over one hundred novel classes of potential antibiotics that were previously undiscovered and thus never analysed for their impact on human health.
“We are committed to bringing urgently needed novel antibiotic medicines to patients, and we are delighted to be collaborating with Roche in that goal,” said Laurence Reid, Warp Drive Bio’s chief executive.
“Antimicrobial resistance is an extraordinary threat to global human health, and Warp Drive’s unique platform allows us to access a vast reservoir of uncharacterised natural products from which to identify novel antibiotics.”
The deal gives Roche an option for an exclusive worldwide license to develop and commercialise certain antibiotic classes that emerge from the collaboration, while Warp Drive will retain worldwide rights to all other novel antibiotic classes.
Warp Drive will receive up to $87 million in upfront payment, option fees, and milestone payments for preclinical events, and up to $300 million in payments related to specific clinical, regulatory and sales milestones on products licensed to Roche. In addition, the firm also stands to receive tiered royalties for products licensed to Roche.
By Selina McKee
Source: Pharma Times
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.
Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.
Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.